Boosting your ADC pipeline with Revvity's Preclinical Services
In the discovery of oncology therapeutics, Antibody-drug conjugates (ADCs) are rapidly gaining momentum, with hundreds of candidates advancing through clinical development. Whether your priority lies in assessing the epitope binding of your construct, evaluating the cytotoxic potency of the payload, or scrutinizing the efficacy of the linker in cleaving, each facet demands meticulous attention.
At Revvity, we specialize in partnering with you to help expedite preclinical in-vitro cell engineering and screening processes for antibody-drug conjugate (ADC) therapeutic candidates through our comprehensive suite of services. This helps streamline development, accelerate progression towards clinical stages.
Our platform:
- From complex in-vitro model design to IND-enabling data generation.
- In-depth analysis covering high-throughput gene, phenotypic, and functional assessments.
- Flexible support ranging from rapid turnaround standard assays to fully customized projects for ADCs.
Screening of ADC candidates
Streamlining therapy efficacy evaluation with monotherapy and combination screens.
Research the delivery of therapeutics to cancer cells in an in-vitro setting, leveraging the powerful capacities of extensive cell panel with complex dosing and multiple readouts.
Streamlining therapy efficacy evaluation with monotherapy and combination screens.
Research the delivery of therapeutics to cancer cells in an in-vitro setting, leveraging the powerful capacities of extensive cell panel with complex dosing and multiple readouts.
Oncosignature™ cell panel screening offers a versatile solution for dose assessment for both solid and liquid tumors, in 2D and 3D formats. It is specially configured for the preclinical analysis of ADC-based combination therapies.
- Combination screen using a library of hundreds of compounds available.
- High resolution combination dose matrices to evaluate enhanced potency across a diverse panel of clinically-relevant cell line models.
- Potential to reveal synergies with small-molecule intracellular pathway inhibitors.
- Multiple readouts capabilities including HTRF™ and high content imaging.
Assessment of payload and linkers
Optimization of ADC design screening across cell panels for therapeutic consistency.
Uncover the power of large cell panel screen platforms for more precise payload selection and efficient drug delivery analysis.
Optimization of ADC design screening across cell panels for therapeutic consistency.
Uncover the power of large cell panel screen platforms for more precise payload selection and efficient drug delivery analysis.
- A spectrum of cytotoxic agents across diverse cancer cell lines to identify the most potent and efficacious payloads.
- Unconventional payloads boasting differentiated mechanisms of action.
- Valuable insights into drug penetration and efficacy within tumor environments in 2D and 3D models.
- Optimization of antibody-drug conjugate design with screening across cell panels, facilitating homogeneity and therapeutic consistency.
- Harness the potential of cleavable and non-cleavable linkers through systematic evaluation, refining bioconjugation methods for enhanced efficacy.
Research mechanisms of action and resistance
Unlocking ADC efficacy with CRISPR technologies.
Pooled and arrayed gene editing screening services identify resistance mechanisms and explore the roles of key regulators in antibody-drug conjugate (ADC) toxicity to boost treatment success.
Unlocking ADC efficacy with CRISPR technologies.
Pooled and arrayed gene editing screening services identify resistance mechanisms and explore the roles of key regulators in antibody-drug conjugate (ADC) toxicity to boost treatment success.
Harness the power of CRISPR technologies by utilizing our comprehensive focused or genome-wide screens to identify and analyze genes that influence antibody-drug conjugate (ADC) toxicity and resistance, providing you with valuable, actionable insights to help enhance your therapeutic strategies.
- Benefit from a comparative analysis of gene-drug interaction for ADCs and different chemistries to understand and overcome resistance mechanisms.
- Identify genes that enhance or inhibit ADC toxicity, paving the way for innovative sensitization approaches that help to maximize treatment impact.
- Partner with us to stay at the forefront of ADC resistance research, leveraging the latest findings to support you to enhance your therapeutic strategies.
Immunogenicity assessment for ADC therapeutics
Unlocking the potential of immune cell-based screening for ADC structure optimization.
Engineer antibody-drug conjugates (ADCs) to enhance or minimize immune involvement based on therapeutic objectives, opening strategic treatment pathways.
Unlocking the potential of immune cell-based screening for ADC structure optimization.
Engineer antibody-drug conjugates (ADCs) to enhance or minimize immune involvement based on therapeutic objectives, opening strategic treatment pathways.
Explore the potential of ImmuSignature™ assays, Revvity´s immune cell-based screening for ADC structure optimization.
- New perspectives of ADC efficacy through immune system recruitment for tumor clearance.
- Selective targeting and reduce the potential of systemic toxicity through immune cell-based screening.
- Evaluate linker stability and payload effectiveness for controlled drug release and cancer cell killing.
- Screening platform designed for rapid assessment of multiple donors for population relevance.
Cell models engineering
Leveraging complex models for efficacy, specificity, and target assessment.
Improving antibody specificity and precise drug delivery to reduce the potential of off-target effects is crucial for antibody-drug conjugates (ADCs) performance.
Leveraging complex models for efficacy, specificity, and target assessment.
Improving antibody specificity and precise drug delivery to reduce the potential of off-target effects is crucial for antibody-drug conjugates (ADCs) performance.
We can support you in enhancing therapeutic outcomes and mitigating risks by leveraging our robust engineered cell lines and advanced knockout and knock-in models through engineering of cell surface targets, including multiplexing base editing with the Pin-point™ platform.
We offer support and innovative solutions to help you advance ADC development, facilitating progress towards clinical stages:
- ADC efficacy through precise antibody binding to target cell surface markers.
- Targeted drug delivery to reduce the impact on healthy tissues.
- Robust models like engineered cell lines for optimized antibody specificity.
- Leverage knockout and knock-in models for comprehensive target assessment.
- Accelerate ADC candidate evaluation with our early-stage screening services using cutting-edge models.
